株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

日本脳炎治療薬のパイプライン分析

Japanese Encephalitis Therapeutics Pipeline Analysis, 2017

発行 Prescient & Strategic Intelligence Private Limited 商品コード 590183
出版日 ページ情報 英文 60 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.67円で換算しております。
Back to Top
日本脳炎治療薬のパイプライン分析 Japanese Encephalitis Therapeutics Pipeline Analysis, 2017
出版日: 2017年10月01日 ページ情報: 英文 60 Pages
概要

当レポートでは、日本脳炎治療薬のパイプラインについて調査し、フェーズ別による分析、臨床試験のレビュー、および主要企業のプロファイルなどを提供しています。

第1章 調査背景

第2章 調査手法

  • 二次調査
  • 一次調査

第3章 エグゼクティブサマリー

第4章 パイプラインの展望

  • 概要
  • 主な促進因子
  • 主な障壁
  • 日本脳炎治療薬のパイプライン分析

第5章 日本脳炎治療薬のパイプライン分析:フェーズ別

  • フェーズIII:薬剤プロファイル
  • 前臨床:薬剤プロファイル
  • 創薬:薬剤プロファイル
  • 不明:薬剤プロファイル
  • 中止:薬剤プロファイル

第6章 臨床試験分析

  • 地域別
  • 試験状況別

第7章 競合情勢

  • 日本脳炎治療薬パイプラインの主要企業ベンチマーキング
  • 日本脳炎治療薬パイプラインのSWOT分析

第8章 企業プロファイル

  • 事業概要
  • 製品・サービス提供

第9章 付録

目次

Japanese encephalitis therapeutics pipeline in 2017

Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.

Insights on pipeline segments

Shandong Hengye Biotech Co., Ltd., and VABIOTECH, have one drug candidates each in the Phase III stage of development for the treatment of the disease. The clinical studies of the vaccine, Vero cell-derived inactivated, is currently going on in China in the Phase III stage of development for the treatment of Japanese encephalitis.

Maximum drugs being developed as vaccines

The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development. Based on molecule type, around 75.0% of the therapeutic candidates are being developed as vaccines, around 13.0% are made as peptide and 12.0% are being developed as small molecule.

Various collaborations for Japanese Encephalitis drug development

In September 2017, VABIOTECH in collaboration with National Institute of Hygiene and Epidemiology (NIHE), Vietnam, initiated a Phase III, randomized, multi-centered, parallel groups assignment trial to assess the immunogenicity and safety of the JECEVAX in healthy male as well as female children of age between nine to 24 months.

Some of the key players developing drugs for the treatment of Japanese encephalitis include Shandong Hengye Biotech, Co. Ltd., Panacea Biotec Ltd., and Ennaid Therapeutics, LLC.

Japanese Encephalitis (JE) Therapeutics Pipeline Analysis

By Phase

By Molecule Type

By Route of Administration

By Company

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Definition
  • 1.3 Research Scope
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

  • 4.1 Overview
  • 4.2 Key Drivers
  • 4.3 Key Barriers
  • 4.4 Japanese Encephalitis Therapeutics Pipeline Analysis
    • 4.4.1 Pipeline Analysis by Phase
    • 4.4.2 Pipeline Analysis by Molecule Type
    • 4.4.3 Pipeline Analysis by Route of Administration
    • 4.4.4 Pipeline Analysis by Company

Chapter 5. Japanese Encephalitis Therapeutics Pipeline Analysis by Phase (2017)

  • 5.1 Phase III: Drug profiles
    • 5.1.1 Pre-Clinical Study
    • 5.1.2 Pre-Clinical Results
    • 5.1.3 Clinical Trials
    • 5.1.4 Clinical Results
    • 5.1.5 Strategic Development
    • 5.1.6 Designation
    • 5.1.7 Grants
    • 5.1.8 Patent
    • 5.1.9 Technology
  • 5.2 Pre-Clinical: Drug profiles
    • 5.2.1 Pre-Clinical Study
    • 5.2.2 Pre-Clinical Results
    • 5.2.3 Strategic Development
    • 5.2.4 Designation
    • 5.2.5 Grants
    • 5.2.6 Patent
    • 5.2.7 Technology
  • 5.3 Discovery: Drug profiles
    • 5.3.1 Strategic Development
    • 5.3.2 Designation
    • 5.3.3 Grants
    • 5.3.4 Patent
    • 5.3.5 Technology
  • 5.4 Unknown: Drug profiles
    • 5.4.1 Pre-Clinical Study
    • 5.4.2 Pre-Clinical Results
    • 5.4.3 Clinical Trials
    • 5.4.4 Clinical Results
    • 5.4.5 Strategic Development
    • 5.4.6 Designation
    • 5.4.7 Grants
    • 5.4.8 Patent
    • 5.4.9 Technology
  • 5.5 Inactive: Drug profiles
    • 5.5.1 Pre-Clinical Study
    • 5.5.2 Pre-Clinical Results
    • 5.5.3 Clinical Trials
    • 5.5.4 Clinical Results
    • 5.5.5 Strategic Development
    • 5.5.6 Designation
    • 5.5.7 Grants
    • 5.5.8 Patent
    • 5.5.9 Technology

Chapter 6. Clinical Trials Analysis

  • 6.1 Clinical Trials by Region for Japanese Encephalitis Therapeutics Pipeline
  • 6.2 Clinical Trials by Trial Status for Japanese Encephalitis Therapeutics Pipeline

Chapter 7. Competitive Landscape

  • 7.1 Key Players Benchmarking for Japanese Encephalitis Therapeutics Pipeline
  • 7.2 SWOT Analysis of Japanese Encephalitis Therapeutics Pipeline
    • 7.2.1 Strengths
    • 7.2.2 Weaknesses
    • 7.2.3 Opportunities
    • 7.2.4 Threats

Chapter 8. Company Profiles

  • 8.1 Business Overview
  • 8.2 Product and Service Offerings

Chapter 9. Appendix

  • 9.1 Abbreviations
  • 9.2 Related Reports

LIST OF TABLES

  • PIPELINE ANALYSIS OF JAPANESE ENCEPHALITIS THERAPEUTICS, BY COMPANY (2017)
  • DESCRIPTION OF PHASE III DRUG CANDIDATES
  • CLINICAL TRIALS OF PHASE III DRUG CANDIDATES
  • DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES
  • DESCRIPTION OF DISCOVERY DRUG CANDIDATES
  • DESCRIPTION OF UNKOWN DRUG CANDIDATES
  • CLINICAL TRIALS OF UNKOWN DRUG CANDIDATES
  • DESCRIPTION OF INACTIVE DRUG CANDIDATES
  • COMPANIES - AT A GLANCE

LIST OF FIGURES

  • RESEARCH METHODOLOGY
  • SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT
  • BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE
  • JAPANESE ENCEPHALITIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
  • JAPANESE ENCEPHALITIS THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)
  • JAPANESE ENCEPHALITIS THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)
  • BREAKDOWN OF CLINICAL TRIALS, BY REGION
  • BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
  • KEY PLAYERS BENCHMARKING
  • SWOT ANALYSIS
Back to Top